Glaucoma is a chronic disease characterised by progressive optic nerve damage and is one of the leading cause of blindness. Glaucoma patients are presumably at a higher risk for developing ocular surface disease (OSD), as both diseases are more common in older patients. Also, topical antiglaucoma drops, as the most common form of treatment, is often associated with OSD symptoms. Long term use of topical treatment could additionally increase symptoms of OSD and, with functional disabilities, affect patient`s quality of life. The purpose of this study was to investigate the relationship between OSD and the self perceived vision – related quality of life in patients with glaucoma using topical antiglaucoma therapy and to determine differences between gender, age and form of therapy. The study included 81 glaucoma patients recruited from the Cabinet for Glaucoma, Department of Ophthalmology, University Hospital Sestre milosrdnice in Zagreb. The data were collected by newly constructed General questionnaire, Ocular Surface Disease Index questionnaire (OSDI) and Visual Function Questionnaire (NEI – VFQ – 39). The data collected were quantitatively analyzed by using ROBDIS, IBM SPSS Statistics software and quazi – canonical analysis. According to the results, 37% patients had severe, while 37% of them showed normal OSDI score. Mild OSDI score had 18,5%, and moderate 7,4%. The most common side effect of therapy is tingling in eye (43,21%), followed by increased redness od the eye (23,46%) and eye dryness (22,22%). Quazi - canonical analysis showed that there is a statistically significant association (p <0.01) between OSD and the vision – related quality of life. After robust discriminatory analysis, significant differences in the quality of life and OSD between gender and age groups and medication therapy were found. These findings support the results of global research that obscure that OSD can undermine the success of therapy and ultimately negatively affect the quality of life of glaucoma patients using local antiglaucoma therapy. Finally, the need for further research into this subject is emphasized, which will provide implications for improving the quality of life of glaucoma patients.